Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

The Dana-Farber Cancer Institute (DFCI) Childhood ALL Consortium Protocol 95-01 was designed to minimize therapy-related morbidity for children with newly diagnosed ALL without compromising efficacy. Patients participated in randomized comparisons of (1) doxorubicin given with or without dexrazoxane...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Moghrabi, Albert, Levy, Donna E., Asselin, Barbara, Barr, Ronald, Clavell, Luis, Hurwitz, Craig, Samson, Yvan, Schorin, Marshall, Dalton, Virginia K., Lipshultz, Steven E., Neuberg, Donna S., Gelber, Richard D., Cohen, Harvey J., Sallan, Stephen E., Silverman, Lewis B.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2007
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC1785142/
https://ncbi.nlm.nih.gov/pubmed/17003366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-06-027714
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires